Study Details

Back to Search Results

A Study of ASP1941 in Combination with Insulin in Patients with Type 1 Diabetes Mellitus

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02897219

Astellas Study ID

The unique identification code given by the study sponsor.

1941-CL-6002

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Juvenile Diabetes

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

20 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Aug 2016 - Mar 2018

Masking

Double (Participant, Investigator)

Enrollment number

175

Phase III Study of ASP1941 Double-blind, Parallel-group Study in Combination with Insulin in Patients with Type 1 Diabetes Mellitus

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP1941 in Combination with Insulin in Patients with Type 1 Diabetes Mellitus? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00024

Nagasaki, Japan

Site JP00016

Kanagawa, Japan

Site JP00034

Hokkaido, Japan

Site JP00023

Fukuoka, Japan

Site JP00019

Mie, Japan

Site JP00001

Tochigi, Japan

Site JP00015

Kanagawa, Japan

Site JP00030

Tokushima, Japan

Site JP00026

Niigata, Japan

Site JP00011

Gunma, Japan

Site JP00031

Fukuoka, Japan

Site JP00010

Ibaraki, Japan

Site JP00003

Chiba, Japan

Site JP00014

Tokyo, Japan

Site JP00008

Nagasaki, Japan

Site JP00029

Osaka, Japan

Site JP00017

Shizuoka, Japan

Site JP00035

Chiba, Japan

Site JP00007

Yamaguchi, Japan

Site JP00018

Shizuoka, Japan

Site JP00032

Nagasaki, Japan

Site JP00006

Hiroshima, Japan

Site JP00022

Fukuoka, Japan

Site JP00033

Hokkaido, Japan

Site JP00027

Toyama, Japan

Site JP00009

Ibaraki, Japan

Site JP00021

Hyogo, Japan

Site JP00028

Aichi, Japan

Site JP00020

Osaka, Japan

Site JP00036

Osaka, Japan

Site JP00025

Nagasaki, Japan

Site JP00012

Saitama, Japan

Site JP00004

Kanagawa, Japan

Site JP00005

Aichi, Japan

Site JP00013

Chiba, Japan

Site JP00002

Gunma, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo